Orphanet J Rare Dis. 2026 Jul 31;21(1):260. doi: 10.1186/s13023-026-04469-1.ABSTRACTBACKGROUND: Rare diseases affect a small percentage of the population but collectively impact millions worldwide. In the Middle East, the challenges are intensified by regional factors such as high rates of consangui
Wiad Lek. 2026;79(6):1194-1202. doi: 10.36740/WLek/221158.ABSTRACTOBJECTIVE: Aim: To describe the clinical picture, laboratory findings, and MEFV mutation profile of FMF children in Duhok, Iraq, and to examine the influence of consanguinity on genotype‑phenotype relationships.PATIENTS AND METHODS: M
No abstractBlood Adv. 2026 Aug 11;10(15):5348-5349. doi: 10.1182/bloodadvances.2026020388.NO ABSTRACTPMID:42536398 | DOI:10.1182/bloodadvances.2026020388
JACC Case Rep. 2026 Jul 31:109541. doi: 10.1016/j.jaccas.2026.109541. Online ahead of print.ABSTRACTBACKGROUND: Wild-type transthyretin amyloid cardiomyopathy (wtATTR-CM) is increasingly recognized with advances in noninvasive imaging and disease-modifying therapies. However, atypical imaging findin
Kidney Dis (Basel). 2026 Jun 15;12(1):635-647. doi: 10.1159/000552894. eCollection 2026 Jan-Dec.ABSTRACTINTRODUCTION: It has been recognized that periodic acid-Schiff (PAS) staining of amyloid deposits is typically weak or negative in the majority of AL amyloidosis. However, a subset of patients exh
Cureus. 2026 Jun 29;18(6):e111747. doi: 10.7759/cureus.111747. eCollection 2026 Jun.ABSTRACTCardiac amyloidosis is a clinical condition characterized by deposition of amyloid fibrils in the myocardium, leading to increased left ventricular wall thickness and ultimately heart failure. We present a ca
Histopathology. 2026 Jul 31. doi: 10.1111/his.70242. Online ahead of print.ABSTRACTAIMS: Monoclonal gammopathy-associated kidney lesions typically present with a single pathological pattern, but the coexistence of multiple patterns in the same patient is rare and poorly characterized. This study aim
Cardiol Ther. 2026 Jul 31. doi: 10.1007/s40119-026-00461-9. Online ahead of print.ABSTRACTINTRODUCTION: Acoramidis, an oral transthyretin stabilizer that achieves near-complete stabilization, is approved for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM) based on the phase 3 study,
RMD Open. 2026 Jul 30;12(3):e006868. doi: 10.1136/rmdopen-2026-006868.ABSTRACTBACKGROUND: Approximately 10%-20% of patients with Kawasaki disease (KD) are resistant to intravenous immunoglobulins (IVIG) and are at increased risk of developing coronary artery aneurysms (CAA). A potential therapeutic
No abstractLancet. 2026 Aug 1;408(10553):381. doi: 10.1016/S0140-6736(26)01548-5.NO ABSTRACTPMID:42532054 | DOI:10.1016/S0140-6736(26)01548-5
ESC Heart Fail. 2026 Jul 30:xvag211. doi: 10.1093/eschf/xvag211. Online ahead of print.ABSTRACTAIMS: Tafamidis was the first drug approved for transthyretin amyloid cardiomyopathy (ATTR-CM), but contemporary real-world evidence is lacking.METHODS AND RESULTS: This retrospective, multicentre study in
Arthritis Rheumatol. 2026 Jul 30. doi: 10.1002/art.70282. Online ahead of print.ABSTRACTOBJECTIVE: Mosaicism is a recognised cause of systemic autoinflammatory diseases (SAIDs). Initially described in Cryopyrin-Associated Periodic Syndromes (CAPS), it has since been reported in several dominantly in
No abstractAmyloid. 2026 Jul 30:1-4. doi: 10.1080/13506129.2026.2711143. Online ahead of print.NO ABSTRACTPMID:42529795 | DOI:10.1080/13506129.2026.2711143
Front Aging Neurosci. 2026 Jul 15;18:1824891. doi: 10.3389/fnagi.2026.1824891. eCollection 2026.ABSTRACTINTRODUCTION: Alzheimer's disease (AD), a neurodegenerative disorder associated with amyloid beta (Aβ) plaque deposition, leads to cognitive decline in affected individuals. Vision changes are amo
Front Cardiovasc Med. 2026 Jul 15;13:1663802. doi: 10.3389/fcvm.2026.1663802. eCollection 2026.ABSTRACTLight chain cardiac amyloidosis (AL-CA) is a severe and progressively infiltrative disease caused by the deposition of misfolded monoclonal immunoglobulin light chains in the myocardial extracellul
Nucl Med Commun. 2026 Jul 30. doi: 10.1097/MNM.0000000000002211. Online ahead of print.ABSTRACTBACKGROUND: Bone scintigraphy with technetium-labeled tracers has become a cornerstone in diagnosing transthyretin cardiac amyloidosis (ATTR-CM). While visual grading systems like the Perugini Score are wi
The optimal choice between sedating histamine H(1) antagonists (sAHs) and non-sedating histamine H(1) antagonists (nsAHs) for preventing infusion-related reactions (IRRs) during daratumumab subcutaneous (DARA-SC) therapy remains unclear. Here, we aimed to compare the efficacy and safety of nsAH and
Heart Fail Rev. 2026 Jul 30;31(1):89. doi: 10.1007/s10741-026-10660-0.ABSTRACTValvular cardiomyopathy has emerged as a key concept linking valvular heart disease (VHD) with myocardial remodeling and the development of heart failure (HF). This state-of-the-art review provides a comprehensive overview
Blood. 2026 Jul 29:blood.2026033437. doi: 10.1182/blood.2026033437. Online ahead of print.ABSTRACTLight chain (AL) amyloidosis is a fatal plasma cell dyscrasia characterized by the overproduction of misfolded l or k immunoglobulin light chains (LCs) produced by clonal plasma cells, which aggregate i
S D Med. 2026 May;79(suppl 5):s30-s31.ABSTRACTINTRODUCTION: Amyloidosis comprises a group of disorders characterized by extracellular deposition of misfolded amyloid proteins within tissues and organs. Tracheobronchial amyloidosis is a rare form of localized amyloidosis involving deposition within t
JAMA Cardiol. 2026 Jul 29:e262413. doi: 10.1001/jamacardio.2026.2413. Online ahead of print.ABSTRACTIMPORTANCE: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), acoramidis achieves near-complete (≥90%) transthyretin stabilization and reduces mortality and cardiovascular-related hospi
No abstractJ Am Coll Cardiol. 2026 Jul 10:S0735-1097(26)06979-2. doi: 10.1016/j.jacc.2026.06.032. Online ahead of print.NO ABSTRACTPMID:42524803 | DOI:10.1016/j.jacc.2026.06.032
No abstractJ Am Coll Cardiol. 2026 Jul 10:S0735-1097(26)06980-9. doi: 10.1016/j.jacc.2026.05.051. Online ahead of print.NO ABSTRACTPMID:42524802 | DOI:10.1016/j.jacc.2026.05.051
Cureus. 2026 Jul 28;18(7):e113520. doi: 10.7759/cureus.113520. eCollection 2026 Jul.ABSTRACTBACKGROUND: Renal amyloidosis results in progressive renal failure, and consistent biopsy reporting improves prognostic accuracy and permits interinstitutional comparisons.OBJECTIVES: This study aims to appl
